CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 3 of the 3 sources its claims cite were checked for support.
Abstract
CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats. Quantifying CagriSema's action on energy intake and expenditure in rats we observe 12% weight loss with a 39% reduction in food intake. By contrast, pair-feeding causes less-pronounced weight loss, while weight matching requires a 51% decrease in food intake. Therefore, approximately one-third of CagriSema's weight loss efficacy arises from an effect on energy expenditure, the blunting of metabolic adaptation, which contributes to the successful treatment of obesity.
Overview
CoChat Summary
## TL;DR
In diet-induced obese male rats, CagriSema produced about 12% weight loss while reducing food intake by 39%, and the authors estimate that roughly one-third of its weight-loss effect came from preserving energy expenditure. Compared with caloric restriction matched for body weight, CagriSema blunted metabolic adaptation and maintained total energy expenditure closer to vehicle levels.
## Key findings
- After 21 days, vehicle-adjusted weight loss was ~12% in the CagriSema (CS) and weight-matched (WM) rats, but only ~8% in pair-fed (PF) rats.
- CS treatment reduced cumulative energy intake by 39%, whereas WM rats required a 51% reduction in energy intake to achieve the same weight loss; cumulative total energy expenditure was similar in vehicle and CS but fell by 17% in WM.
- Based on the area between the CS and PF curves, 28% of the weight loss was attributed to energy expenditure and 72% to energy intake; by 3 weeks, the energy-expenditure contribution reached 34%.
- In pooled analysis of 145 rats, final total energy expenditure did not differ between vehicle and drug-treated groups, but was greater than in calorically restricted rats (V versus WM + PF, P < 0.0001; CS + C + S versus WM + PF, P < 0.0001; CS + C + S versus V, P = 0.97).
## Methods
- Diet-induced obese male Sprague Dawley rats were studied in five independent energy-expenditure experiments; treatments included vehicle, CagriSema, cagrilintide alone, semaglutide alone, pair-feeding, and weight-matching.
- Rats were housed under controlled light/dark and temperature conditions, and energy intake, total energy expenditure, respiratory exchange ratio, body weight, body composition, and core body temperature were measured; one pooled analysis combined 145 rats (vehicle n = 38, drug n = 57, calorie restriction n = 50).
- The main analyses used ANOVA, ANCOVA, mixed-model ANCOVA, and differential expression analysis of liver and skeletal muscle RNA-seq data; pathway enrichment was performed on significant genes.
## Limitations
- The paper states that “further testing” is needed in longer studies, in females, across other diets and species, and in species without substantial brown adipose thermogenesis.
- It also states that the human relevance remains unproven; the cited human support is from a clinical study of a different drug and is noted as being hampered by lack of weight matching in the control group.
- Evident from the text: the study is in male rats only, so sex differences were not assessed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
3 Valid · 0 Not valid · 0 Not checked · 61 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although hampered by lack of weight matching in the control group, a clinical study of the dual GLP-1–glucagon receptor agonist SAR435899 (bamadutide) supports that pharmacological attenuation of metabolic adaptation is indeed a biological possibility in humans16.”
§ CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure > Main
What the sources say
- Partly supportedcites [16] Corbin, K. D. et al. Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: a randomized trial. Obesity (Silver Spring) 31, 350–362 (2023). sourceExperimental — accuracy not yet measured
The Results (page unavailable) report that treatment blunted metabolic adaptation during sleep compared with placebo, supporting the claim's biological point in humans. The Abstract Results also report greater weight loss in the treatment group, consistent with the citing sentence's caveat. However, the paper identifies the agonist as SAR425899, not SAR435899; the provided passages do not identify it as bamadutide. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cumulative total energy expenditure (TEE) during treatment was similar in the V and CS cohorts, but was reduced by 17% in the WM rats (P = 0.008) (Fig. 1g,h).”
§ CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure > Main
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Quantifying CagriSema’s action on energy intake and expenditure in rats we observe 12% weight loss with a 39% reduction in food intake.”
- Also stated in: § Main · plain
“Thus, the vehicle-adjusted weight loss was ~12% in the CS and WM rats, but only ~8% in the PF animals (Fig. 1c).”
§ CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Main · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cumulative total energy expenditure (TEE) during treatment was similar in the V and CS cohorts, but was reduced by 17% in the WM rats (P = 0.008) (Fig. 1g,h).”
§ CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure > Main
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the WM group, the required EI restriction plateaued at 40% below baseline.”
§ CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure > Main
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
25 more claims
Create a free account to see all 64 claims and every source verdict.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 27
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219 · cited 1×
“Subsequently, unique gene hit counts were calculated using featureCounts from the Subread package v.1.5.2 by summarizing and reporting the hit counts based on the gene id feature in the annotation file 26 .”
InfluentialThe Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807 · cited 1×
“In addition, the Molecular Signature Database 29 was used to investigate the hallmark gene sets.”
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data
(2021) · doi:10.1016/j.xinn.2021.100141 · Cited by 12,455
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Ultrafast one‐pass FASTQ data preprocessing, quality control, and deduplication using fastp
Chen, S. (2023) · iMeta · doi:10.1002/imt2.107 · Cited by 2,166
The Biology of Human Starvation: Volume I
KEYS, A., BROŽEK, J., HENSCHEL, A., MICKELSEN, O., & TAYLOR, H. L. (1950) · doi:10.5749/j.ctv9b2tqv · Cited by 2,039
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 3×
“Data are presented as mean ± s.e.m. Graphs were created in GraphPad Prism 9 and figures were edited in Adobe Illustrator (Adobe Systems).”
Cited by
Kuhre, R. E., Ballarín-González, B., Brand, C. L., Glendorf, T., Madsen, K. G., Hjøllund, K. R., Hogendorf, W. F. J., Ipsen, D. H., Lundh, S. H., Kruse, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105862 · Cited by 29
Self-citationThe story of amylin: from physiology to therapy
Secher, A., Lutz, T. A., & Raun, K. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01465-4 · Cited by 16
Self-citationØstergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
Metabolic and appetitive regulation of adipocyte mass during treatment of obesity
Purnell, J. Q., & le Roux, C. W. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70045 · Cited by 9
Self-citationLeptin and G-protein coupled receptor (GPCR) signaling: Therapeutic potential in obesity
Sun, X., Brueck, L., Yang, D., Sheets, P. L., Zhou, B., & Ren, H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110768 · Cited by 5
Metadata
- Authors
- Jacobsen, J. M., Halling, J. F., Blom, I., Moreno Martinez, J., Hald, B., Pedersen, K., Fels, J. J., Snitker, S., Secher, A., Lundh, S., le Roux, C. W., Raun, K., Reitman, M. L., & Kuhre, R. E.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- University of Copenhagen (DK)
- National Institutes of Health (US)
- Corresponding author
- Kuhre, Rune Ehrenreich
- ORCID
- Venue
- Nature Metabolism
- Published
- 2025-07-08
- Volume
- 7
- Issue
- 7
- Pages
- 1322-1329
- ISSN
- 2522-5812 (ISSN-L)
- PMC
- PMC12286864
- OpenAlex
- W4412102616
- Cited by
- 15
- References
- 29
- Citations by year
- 2026: 11 · 2025: 4
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Nature Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- Funders
- Novo Nordisk
- Foundation for the National Institutes of Health (ZIA DK075062)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- cagrilintide, semaglutide, amylin analogues, GLP-1 analogues, weight loss, energy intake, energy expenditure, metabolic adaptation, obesity treatment, hypophagia, pair feeding
- MeSH terms
- Animals, Energy Intake, Eating, Energy Metabolism, Male, Obesity, Weight Loss, Rats, Glucagon-Like Peptide 1, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure. https://app.cochat.ai/papers/10.1038/s42255-025-01324-8
- The paper
- Jacobsen, J. M., Halling, J. F., Blom, I., Moreno Martinez, J., Hald, B., Pedersen, K., Fels, J. J., Snitker, S., Secher, A., Lundh, S., le Roux, C. W., Raun, K., Reitman, M. L., & Kuhre, R. E. (2025). CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure. Nature Metabolism. https://doi.org/10.1038/s42255-025-01324-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.